ArticleScientific reports2022
Population-based survival for cancer patients in Saudi Arabia for the years 2005-2009.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study.Endocrine · 2023Pooled it
- Impact of underweight on patients receiving curative-intent anticancer therapy: analysis of a large oncology database in Saudi Arabia.BMC cancer · 2026Observational
- Linking local cancer registries and national death records: a crucial step for accurate survival data in Saudi Arabia.BMC health services research · 2025Article
- Nationwide Prevalence of Hepatocellular Carcinoma in Saudi Arabia: A Population-Based Analysis for 2021.Journal of hepatocellular carcinoma · 2025Article
- Monitoring Ototoxicity in Cancer Patients Undergoing Platinum-Based Chemotherapy and Radiation in Saudi Arabia: Challenges and Solutions.Journal of multidisciplinary healthcare · 2025Article
- Practice Patterns of Palliative Radiotherapy for Advanced Cancer at a Large Institute in Saudi Arabia.Palliative medicine reports · 2025Article
- Predictors of thyroid cancer survival in Saudi Arabia: A retrospective 10-year analysis.Qatar medical journal · 2024Article
- Breast Cancer in the Arabian Gulf Countries.Cancers · 2023Review
- Article
- Risk of Breast Cancer Progression after Treatment in the Western Region of Saudi Arabia.Breast cancer : basic and clinical research · 2023Article
- The 30-day hospital readmission and mortality after surgery in colorectal cancer patients.BMC gastroenterology · 2022Article
- Outcomes and Prognostic Factors of Metastatic Gastric Cancer: A Single-Center Experience.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Saudi Cancer Registry reported in 2007 the 5-year observed survival for the most common cancer sites for the years 1994-2004. In this report we looked at the cancer survival in the period 2005-2009 and evaluated the trend over the 15 years period from 1994 to 2009. Cases of the top 14 cancer sites reported by the population based Saudi Cancer Registry from 1 January 2005 to December 31, 2009, were submitted for survival analysis. The vital status of those patients was collected. Analysis of survival for the above period was compared with the prior reported 2 periods (1994-1999, 2000-2004). In addition, analysis was done according to age, sex, disease stage and the province. Data of 25,969 patients of the commonest cancer sites were submitted. Of those 14,146 patients (54%) had complete demographic data available and vital status was reported. Thyroid cancer had the highest 5- year observed survival of 94% (95% confidence interval (CI) 93-95%)), followed by Breast (72%, 95% CI 71-74%). In hematological malignancies, Hodgkin's Lymphoma had the highest 5-year survival of 86% (95% CI 84-88%). Survival rates has improved in most of the cancers sites for the studied periods except for lung, uterine and Hodgkin's lymphoma which plateaued. Our study confirms a steady improvement in the 5-year observed survival over time for the majority of cancers. Our survival data were comparable to western countries. This data should be used by policy makers to improve on cancer care in the kingdom.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.